Liquidia Technologies is applying its novel PRINT® technology toward internal, licensed, and co-development opportunities, including:

  • Internal development of LIQ861 for pulmonary arterial hypertension and LIQ865 for post-surgical pain
  • Partnerships with leading pharmaceutical companies such as GlaxoSmithKline and others undisclosed

*Liquidia has additional programs being developed through undisclosed collaborations not shown on this pipeline

© 2018 Liquidia Technologies